doi: 10.1002/mds.22879.
Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view
- PMID: 20155864
- DOI: 10.1002/mds.22879
Item in Clipboard
Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view
Mov Disord.
.
No abstract available
Similar articles
-
Neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view.Mov Disord. 2010 Apr 15;25(5):660-1. doi: 10.1002/mds.22878. Mov Disord. 2010. PMID: 20213824 No abstract available.
-
Has "levodopa-induced neuropathy" been reported in Parkinson's disease clinical trials?Mov Disord. 2011 Aug 15;26(10):1966-7. doi: 10.1002/mds.23760. Epub 2011 May 12. Mov Disord. 2011. PMID: 21567458 No abstract available.
-
"Double crush" in Parkinson's disease.Ann Neurol. 2010 Dec;68(6):972; author reply 973. doi: 10.1002/ana.22260. Ann Neurol. 2010. PMID: 21194160 No abstract available.
-
Rating scales for dyskinesias in Parkinson's disease.Mov Disord. 1999;14 Suppl 1:48-53. Mov Disord. 1999. PMID: 10493403 Review. No abstract available.
-
[Pharmacological therapy of complicated Parkinson's disease].Rev Neurol. 1997 Aug;25 Suppl 2:S170-9. Rev Neurol. 1997. PMID: 9280685 Review. Spanish.
Cited by
-
Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.J Neural Transm (Vienna). 2011 Sep;118(9):1329-33. doi: 10.1007/s00702-011-0614-9. Epub 2011 Feb 27. J Neural Transm (Vienna). 2011. PMID: 21359971 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
